A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of ZN-e4 (KP-673) in Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor (EGFR) Mutations
Phase of Trial: Phase I/II
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs ZN-e4 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Zeno Pharmaceuticals
- 18 Jul 2019 Planned number of patients changed from 100 to 140.
- 18 Jul 2019 Planned End Date changed from 20 Dec 2020 to 20 Dec 2022.
- 18 Jul 2019 Planned primary completion date changed from 20 Mar 2020 to 20 Jun 2022.